Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-020-18096-2 http://scihub22266oqcxt.onion/10.1038/s41467-020-18096-2 32855413!7453019!32855413     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2020 ; 11 (1): 4282 Nephropedia Template TP {{tp|p=32855413|t=2020. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication |pdf=|usr=}}{{32855413}} gab.com Text Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=32855413 #FOAvip The main protease, M(pro) (or 3CL(pro)) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M(pro) from both SARS-CoV and SARS-CoV-2 with IC(50) values in the nanomolar range. Crystal structures of SARS-CoV-2 M(pro) with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19. Twit Text FOAVip Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=32855413 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32855413 #FOAvip English Wikipedia <ref>{{Cite pmid|32855413}}</ref> Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication #MMPMID32855413 Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ Nat Commun 2020[Aug]; 11 (1): 4282 PMID32855413show ga The main protease, M(pro) (or 3CL(pro)) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M(pro) from both SARS-CoV and SARS-CoV-2 with IC(50) values in the nanomolar range. Crystal structures of SARS-CoV-2 M(pro) with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19. |A549 Cells[MESH] |Animals[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Betacoronavirus/*drug effects/enzymology[MESH] |Binding Sites[MESH] |Chlorocebus aethiops[MESH] |Coronavirus 3C Proteases[MESH] |Coronavirus, Feline/*drug effects/enzymology[MESH] |Crystallography, X-Ray[MESH] |Cysteine Endopeptidases/chemistry[MESH] |Cytopathogenic Effect, Viral/drug effects[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Inhibitory Concentration 50[MESH] |Molecular Structure[MESH] |Prodrugs[MESH] |Protease Inhibitors/chemistry/*pharmacology[MESH] |Pyrrolidines/chemistry/pharmacology[MESH] |SARS-CoV-2[MESH] |Severe acute respiratory syndrome-related coronavirus/drug effects/enzymology[MESH] |Sulfonic Acids[MESH] |Vero Cells[MESH] |Viral Nonstructural Proteins/*antagonists & inhibitors/chemistry[MESH]Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and b(epmc).pdf DeepDyve Pubget Overpricing